BOSTON — The maker of Vyvanse successfully sought dismissal of a putative consumer protection class action, which was brought by a patient who says she was given medicine with less of the active ingredient in them than the label indicated. She received empty pills, and some were deficient in the amount of medication in them, but she could not show how this rose above to the level of a breach of warranty or deceptive practices, rather than a mere error or negligence.
Read the ruling here.
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Search Articles
